1.A comparison of R-CHOP and R-DA-EPOCH as a first-line regimen treatment of diffuse large B cell lymphoma with non-GCB subtypes: a retrospective study.
Zi Yan HE ; Wen Juan YU ; Shan Shan SUO ; Jing Han WANG ; Hai Tao MENG ; Wen Yuan MAI ; Ju Ying WEI ; Min YANG ; Li Ping MAO ; Jie JIN
Chinese Journal of Hematology 2022;43(4):346-348
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
;
Cyclophosphamide/therapeutic use*
;
Doxorubicin/therapeutic use*
;
Etoposide
;
Humans
;
Lymphoma, Large B-Cell, Diffuse/pathology*
;
Prednisone/therapeutic use*
;
Prognosis
;
Retrospective Studies
;
Rituximab/therapeutic use*
;
Vincristine/therapeutic use*
2.Risk factors for acute kidney injury after hematopoietic stem cell transplantation in children: a retrospective study.
Jian LIU ; Zhi-Wei CHEN ; Ying-Jie WANG ; Yu-Miao MAI ; Hui-Hui HU ; Bing REN ; Ying-Chao WANG ; Yu-Feng LIU
Chinese Journal of Contemporary Pediatrics 2022;24(10):1136-1142
OBJECTIVES:
To investigate the risk factors for acute kidney injury (AKI) after hematopoietic stem cell transplantation (HSCT) in children.
METHODS:
A retrospective analysis was performed on the medical data of 111 children who underwent HSCT from January 2018 to January 2020. A multivariate logistic regression analysis was used to identify the risk factors for AKI. The Kaplan-Meier survival analysis was used to compare the prognosis in children with different grades of AKI.
RESULTS:
Graft-versus-host disease (grade Ⅱ-Ⅳ) (OR=4.406, 95%CI: 1.501-12.933, P=0.007), hepatic veno-occlusive disease (OR=4.190, 95%CI: 1.191-14.740, P=0.026), and thrombotic microangiopathy (OR=10.441, 95%CI: 1.148-94.995, P=0.037) were closely associated with the development of AKI after HSCT. The children with stage Ⅲ AKI had a lower 1-year survival rate than those without AKI or with stage Ⅰ AKI or stage Ⅱ AKI (28.6%±12.1% vs 82.8%±5.2%/81.7%±7.4%/68.8%±11.6%; P<0.05).
CONCLUSIONS
Children with stage Ⅲ AKI after HSCT have a higher mortality rate. Graft-versus-host disease, hepatic veno-occlusive disease, and thrombotic microangiopathy are closely associated with the development of AKI after HSCT.
Child
;
Humans
;
Retrospective Studies
;
Hematopoietic Stem Cell Transplantation/adverse effects*
;
Graft vs Host Disease/complications*
;
Risk Factors
;
Acute Kidney Injury/therapy*
;
Thrombotic Microangiopathies/complications*
3. Comparison of clinical pregnancy rates between two types of endometrial preparation protocols for patients with thin endometrium in frozen-thawed embryo transfer cycles
Hui-ying JIE ; Lu LUO ; Yu FU ; Xiong-zhi FAN ; Qing-yun MAI ; Can-quan ZHOU
Chinese Journal of Practical Gynecology and Obstetrics 2019;35(09):1023-1026
OBJECTIVE: To compare the clinical pregnancy rates between two types of endometrial preparation protocolsnatural cycle(NC)and hormone replacement cycle(HRT)-in patients with thin endometrium in the frozen-thawed embryo transfer(FET)cycles.METHODS: From January 2012 to December 2018,FET patients with endometrial thickness ≤7 mm on the day of human chorionic gonadotropin(h CG)trigger in Reproductive Medicine Center of the First Affiliated Hospital of Sun Yat-sen University were selected as research subjects.According to the endometrial preparation protocols,they were divided into NC group and HRT group.Totally 117 pairs were successfully matched using the propensity score matching method.The matching variables were age,embryo type and number of transferred embryos,and the embryo implantation rate and clinical pregnancy rate of the two matched groups were compared.RESULTS: There was no significant difference in embryo implantation rate(36.47% vs. 39.03%)or clinical pregnancy rate(44.40% vs. 52.10%)between NC group and HRT group(P> 0.05).CONCLUSION: NC group and HRT group had similar pregnancy rate in patients with thin endometrium in FET cycles.Individualized protocols can be adopted according to the characteristics of patients with thin endometrium.
4.A modified protocol of mouse hippocampal primary microglia culture by using manual dissociation, magnetic activated cell sorting and TIC medium.
Ya-Nan XU ; Li-Jun ZHOU ; Ying-Tao JIE ; Chun-Lin MAI ; Jun ZHANG ; Zhen-Jia LIN ; Zhi TAN
Acta Physiologica Sinica 2019;71(6):883-893
In this study, we improved the culture method of mouse hippocampal primary microglia to obtain hippocampal ramified microglia with high activity and purity, which were resemble to the resting status of normal microglia in healthy brain in vivo. Hippocampal tissue was excised from 2-4-week-old SPF C57BL/6J mice and cut into pieces after PBS perfusion, and then manually dissociated into the single-cell suspension by using Miltenyi Biotec's Adult Brain Dissociation Kit. The tissue fragments such as myelin in the supernatant were removed by debris removal solution in the kit. The cell suspension was incubated with CD11b immunomagnetic beads for 15 min at 4 °C. To obtain high-purity microglia, we used two consecutive cell-sorting steps by magnetic activated cell sorting (MACS). After centrifugation, the cells were resuspended and seeded in a 24-well culture plate. The primary microglia were cultured with complete medium (CM) or TIC medium (a serum-free medium with TGF-β, IL-34 and cholesterol as the main nutritional components) for 4 days, and then were used for further experiments. The results showed that: (1) The cell viability was (56.03 ± 2.10)% by manual dissociation of hippocampus; (2) Compared with immunopanning, two-step MACS sorting allowed for efficient enrichment of microglia with higher purity of (86.20 ± 0.68)%; (3) After being incubated in TIC medium for 4 d, microglia exhibited branching, quiescent morphology; (4) The results from qRT-PCR assay showed that the levels of TNF-α, IL-1β and CCL2 mRNA in TIC cultured-microglia were similar to freshly isolated microglia, while those were much higher in CM cultured-microglia after incubation for 4 d and 7 d (P < 0.05). Taken together, compared to the conventional approaches, this modified protocol of mouse hippocampal primary microglia culture by using MACS and TIC medium enables the increased yield and purity of microglia in the quiescent state, which is similar to normal ramified microglia in healthy brain in vivo.
Animals
;
Cell Culture Techniques
;
methods
;
Cell Separation
;
methods
;
Cells, Cultured
;
Hippocampus
;
Magnetics
;
Mice
;
Mice, Inbred C57BL
;
Microglia
;
cytology
5.Therapeutic effect of subtotal parathyroidectomy for 72 uremic patients with secondary hyperparathyroidism
yuan Heng GAO ; Nan XU ; peng Xun LUO ; jie Xin LIU ; xian Dong ZHOU ; cheng Pei MAI ; ying Gui ZHANG
Chinese Journal of Current Advances in General Surgery 2017;20(9):684-686,691
Objective:To retrospectively analyze the therapeutic effect of subtotal parathyroidectomy (sT-PTX) on uremic patients with secondary hyperparathyroidism (SHPT).Methods:Seventy two SHPT patients treated with sT-PTX in our hospital were enrolled in this study.Serum parathyroid hormone(PTH),calcium(Ca) and phosphorus(P) obtained in the preoperative,postoperative and followup periods were collected and compared.Their symptoms,postoperative complications and relapse were recorded.Results:(1)sT-PTX operation performed successfully in 70/72 patients(97.2%).(2)After sT-PTX,bone pain and itching improved rapidly,with the improvement of nutritional status,Partial patients with renal hypertension were remitted compared with preoperative.Thirteen cases can walk without wheelchair after sT-PTX.(3)Serum PTH,Ca,and P decreased significantly after sT-PTX for one week,one month and 6 months as compared with those before sT-PTX(P<0.05).(4)Postoperative hypocalcemia was frequently seen(53/72,53.6%) but could be effectively controlled by intravenous calcium infusion.(5)SHPT recurred in the 6 months after sT-PTX in 4 cases (5.7%).Conclusions:T-PTX can effectively decrease PTH level and improve symptoms,and is a safe measure for the treatment of uremic patients with SHPT.
6.Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter,cross-sectional survey
Huang HUI-YAO ; Shi JU-FANG ; Guo LAN-WEI ; Bai YA-NA ; Liao XIAN-ZHEN ; Liu GUO-XIANG ; Mao A-YAN ; Ren JIAN-SONG ; Sun XIAO-JIE ; Zhu XIN-YU ; Wang LE ; Song BING-BING ; Du LING-BIN ; Zhu LIN ; Gong JI-YONG ; Zhou QI ; Liu YU-QIN ; Cao RONG ; Mai LING ; Lan LI ; Sun XIAO-HUA ; Ren YING ; Zhou JIN-YI ; Wang YUAN-ZHENG ; Qi XIAO ; Lou PEI-AN ; Shi DIAN ; Li NI ; Zhang KAI ; He JIE ; Dai MIN
Chinese Journal of Cancer 2017;36(8):352-366
Background:The increasing prevalence of colorectal cancer (CRC) in China and the paucity of information about relevant expenditure highlight the necessity of better understanding the financial burden and effect of CRC diagnosis and treatment.We performed a survey to quantify the direct medical and non-medical expenditure as well as the resulting financial burden of CRC patients in China.Methods:We conducted a multicenter,cross-sectional survey in 37 tertiary hospitals in 13 provinces across China between 2012 and 2014.Each enrolled patient was interviewed using a structured questionnaire.All expenditure data were inflated to the 2014 Chinese Yuan (CNY;1 CNY =0.163 USD).We quantified the overall expenditure and financial burden and by subgroup (hospital type,age at diagnosis,sex,education,occupation,insurance type,household income,clinical stage,pathologic type,and therapeutic regimen).We then performed generalized linear modeling to determine the factors associated with overall expenditure.Results:A total of 2356 patients with a mean age of 57.4 years were included,57.1% of whom were men;13.9% of patients had stage Ⅰ cancer;and the average previous-year household income was 54,525 CNY.The overall average direct expenditure per patient was estimated to be 67,408 CNY,and the expenditures for stage Ⅰ,Ⅱ,Ⅲll,and Ⅳ disease were 56,099 CNY,59,952 CNY,67,292 CNY,and 82,729 CNY,respectively.Non-medical expenditure accounted for 8.3% of the overall expenditure.The 1-year out-of-pocket expenditure of a newly diagnosed patient was 32,649 CNY,which accounted for 59.9% of their previous-year household income and caused 75.0% of families to suffer an unmanageable financial burden.Univariate analysis showed that financial burden and overall expenditure differed in almost all subgroups (P < 0.05),except for sex.Multivariate analysis showed that patients who were treated in specialized hospitals and those who were diagnosed with adenocarcinoma or diagnosed at a later stage were likely to spend more,whereas those with a lower household income and those who underwent surgery spent less (all P < 0.05).Conclusions:For patients in China,direct expenditure for the diagnosis and treatment of CRC seemed catastrophic,and non-medical expenditure was non-ignorable.The financial burden varied among subgroups,especially among patients with different clinical stages of disease,which suggests that,in China,CRC screening might be cost-effective.
7.Therapeutic Efficacy of VICP+L-ASP/TKI on Adult Patients with B-ALL.
Ming-Fang SHEN ; Ju-Ying WEI ; Wen-Juan YU ; Jing-Han WANG ; Hong-Yan TONG ; Hai-Tao MENG ; Wen-Yuan MAI ; Wen-Bin QIAN ; Jie JIN
Journal of Experimental Hematology 2016;24(6):1730-1736
OBJECTIVETo evaluate the therapeutic efficacy of VICP+L-ASP/TKI on adult patients with B-ALL and to explore the influence factors.
METHODSForty-one adult B-ALL patients treated with VICP+L-ASP/TKI from August 2008 to June 2014 were following-up. The complete remission(CR) rate, toxicity, overall survival(OS) and event free survival(EFS) after induction treatment were analyzed, the therapeutic outcome of patients between different risk stratification subgroups was compared, the influence of standardized consolidatory and maintaining treatment as well as allogeneic hematopoietic stem cell transplantation(allo-HSCT) on survival time was analyzed.
RESULTSThe early death not occurred in 41 patients with B-ALL including 37 cases with CR; the CR rate of 1 course treatment was 90.2%. The follow-up time lasted to March 17, 2015, the median follow-up time was 25(9-79) months; the 1 year OS rate was 75.3%, the EFS rate was 58.3%. Analysis of risk factors showed that the initial WBC count over 30×10/L, LDH over 250 U/L and minimal residual disease(MRD) over 10after treatment were poor prognostic factors. After remission, the standardized consolidatory treatment or allo-HSCT according to the "2012 China adult ALL diagnosis and treatment expert consensus" could improve long-term survival, 3 years OS rate was 73.8% and 61.5% respectively, 3 years EFS were 63.5% and 65.7% respectively. The main toxic and side effects were hematologic reactions, the hematologic adverse reaction of IV grade was observed in 97.6%(40/41) during induction treatment.
CONCLUSIONInduction chemotherapy based on VICP+L-ASP/TKI and standardized consolidatory after remission according to the "2012 China adult acute lymphoblastic leukemia diagnosis and treatment expert consensus" can improve the therapeutic efficacy. The allo-HSCT should be actively performed for B-ALL paients with high risk(elevated initial WBC count and LDH level); at some time, the regularly monitoring MRD and adjusting therapeutic protocol according to monitoring result can promote the prognosis of adult B-ALL patients.
8.The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients.
Ying LU ; Fenglin LI ; Qitian MU ; Haitao MENG ; Wenbin QIAN ; Hongyan TONG ; Wenyuan MAI ; Renzhi PEI ; Mengxia YU ; Xiaoying ZHAO ; Jie JIN
Chinese Journal of Hematology 2015;36(5):372-377
OBJECTIVETo investigate the clinical efficacy of all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) in induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia (APL).
METHODSA retrospective analysis of 298 newly diagnosed APL patients from the department of hematology, First Affiliated Hospital of Zhejiang University since September 2004 to December 2013, including 177 cases with ATRA plus ATO and 116 ATRA plus chemotherapy (CT), was performed to investigate the clinical efficacy between the low-intermediate (WBC≤10×10⁹/L) and high (WBC>10×10⁹/L) risk APL patients, respectively.
RESULTSFor the low-intermediate risk patients, the relapse rate in ATRA plus CT and ATRA plus ATO are 22.0% and 6.1% (P=0.004), respectively; the 3 years estimated relapse-free survival (RFS) are 78.0% and 92.9% (P=0.021), respectively. For the high risk patients, the relapse rate in ATRA plus CT and ATRA plus ATO are 25.0% and 5.2% (P=0.035), respectively; the 3 years estimated RFS rate were 80.8% and 93.0% (P=0.021), respectively. But the rate of early death (ED), complete remission (CR) and overall survival (OS) between the two therapy protocols had no statistical difference (P>0.05).
CONCLUSIONATRA plus ATO in induction and maintenance therapy might prolong the RFS time of the low-intermediate risk APL patients and decrease the relapse rate of the low, intermediate and high risk APL patients.
Antineoplastic Combined Chemotherapy Protocols ; Arsenicals ; Humans ; Leukemia, Promyelocytic, Acute ; Oxides ; Recurrence ; Remission Induction ; Retrospective Studies ; Survival Rate ; Tretinoin
9.Research advances in corneal newborn lymphatic vessel and corneal transplantation rejection
Jie-Ying, MAI ; Xian-Ling, TANG ; Ping, LIU
International Eye Science 2014;(12):2168-2171
Corneal newborn lymphatic vessels construct the afferent arc of corneal immunological reaction, which play important role in immune response. The corneal transplantation rejection rate rises due to the emergence of new lymphatic vessel which breaks the immunologic mechanism. With the founding of specific marker of lymphatic endothelial cells and research advancing of growth factor of lymphatic vessels, the mechanism, therapy and prevention of corneal immunological rejection reaction of corneal lymphatic vessel have been studied intensively. The graft survival rate has been greatly improved through inhibiting newborn lymphatic vessel.
10.Effect of individualized rehabilitation training process on the life quality of stroke patients
Bin-Ying HUANG ; Ya-Jie LI ; Li-Min SUN ; Juan WEI ; Xiao-Hua YANG ; Feng-Jiao MAI
Chinese Journal of Modern Nursing 2012;18(32):3854-3859
Objective To explore the effects of individualized rehabilitation training process on the life quality (QOL) of patients with stroke.Methods Totals of 120 cases were randomly divided into observational group (n =60) and control group (n =60),both groups were given neurological routine care,and the observational group was furthermore implemented individualized rehabilitation training process according to Motor Relearning Progarn (MRP) and Burnnstom Disease Staging.Then,they were investigated with the SF-36 before intervention,three days before discharge,1 month,3 month and 6 month after discharge,respectively.Results The total QOL scores were (321.22 ± 17.80),(447.93 ± 19.04),(509.80 ± 20.27),(543.91 ± 46.78),(579.31 ± 44.87) in observational group before intervention,three days before discharge,1 month,3 month,and 6 month after discharge,respectively,while in control group were (322.22 ± 19.15),(443.58 ±22.55),(472.25 ± 21.02),(471.82 ± 29.53).Results showed that the total QOL scores in the observational group was increasing progressively with the extension of intervention time.It reached peak at 6th month after discharge.And there were significantly difference in total QOL scores comparing among different time points except for 1,3 month after discharge (F =633.469,402.503,1044.881,69.654,respectively ; P < 0.05).The control groups results showed that the total QOL scores raised correspondingly with time extension,but the rate of climb was mild after discharge,and no significant difference between the first and third month after discharge was found (P =0.930).Conclusions The individualized rehabilitation training process could improve the patients' survival quality.

Result Analysis
Print
Save
E-mail